Brokerages Set Puma Biotechnology Inc (PBYI) PT at $102.22

Puma Biotechnology Inc (NASDAQ:PBYI) has received a consensus recommendation of “Hold” from the twelve analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $102.22.

A number of brokerages have issued reports on PBYI. Stifel Nicolaus set a $95.00 price target on shares of Puma Biotechnology and gave the stock a “buy” rating in a report on Friday, March 9th. BidaskClub lowered shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Saturday, March 3rd. Credit Suisse Group set a $106.00 price target on shares of Puma Biotechnology and gave the stock a “buy” rating in a report on Friday, March 2nd. Barclays lowered shares of Puma Biotechnology from an “overweight” rating to an “equal weight” rating and set a $90.00 price target on the stock. in a report on Thursday, April 12th. Finally, Zacks Investment Research raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a report on Monday, May 7th.

Puma Biotechnology traded up $0.60, reaching $54.70, during trading hours on Monday, MarketBeat.com reports. The company’s stock had a trading volume of 1,732,502 shares, compared to its average volume of 633,289. Puma Biotechnology has a 1 year low of $47.00 and a 1 year high of $136.90. The company has a current ratio of 1.91, a quick ratio of 1.87 and a debt-to-equity ratio of 0.85.



Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.61. The business had revenue of $66.50 million during the quarter, compared to analysts’ expectations of $67.33 million. During the same quarter in the previous year, the business earned ($1.16) EPS. sell-side analysts forecast that Puma Biotechnology will post -3.83 EPS for the current fiscal year.

In other news, insider Charles R. Eyler sold 1,211 shares of Puma Biotechnology stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $53.00, for a total transaction of $64,183.00. Following the sale, the insider now owns 35,816 shares of the company’s stock, valued at approximately $1,898,248. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 21.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Redwood Investments LLC boosted its stake in shares of Puma Biotechnology by 8.5% during the 1st quarter. Redwood Investments LLC now owns 194,773 shares of the biopharmaceutical company’s stock valued at $13,254,000 after purchasing an additional 15,178 shares in the last quarter. Summit Trail Advisors LLC boosted its stake in shares of Puma Biotechnology by 36.3% during the 1st quarter. Summit Trail Advisors LLC now owns 7,671 shares of the biopharmaceutical company’s stock valued at $307,000 after purchasing an additional 2,041 shares in the last quarter. Xact Kapitalforvaltning AB boosted its stake in shares of Puma Biotechnology by 50.7% during the 1st quarter. Xact Kapitalforvaltning AB now owns 4,458 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 1,500 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Puma Biotechnology by 271.3% during the 1st quarter. Royal Bank of Canada now owns 4,021 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 2,938 shares in the last quarter. Finally, PointState Capital LP boosted its stake in shares of Puma Biotechnology by 39.9% during the 1st quarter. PointState Capital LP now owns 315,183 shares of the biopharmaceutical company’s stock valued at $21,448,000 after purchasing an additional 89,951 shares in the last quarter. 91.82% of the stock is currently owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply